Analystreport

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.

Aktis Oncology, Inc. - Common stock  (AKTS) 
NASDAQ:AMEX Investor Relations: ir.akoustis.com